Biphasic or Mixed
Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatin
Cancer Research Communications 2025 December 10 [Link] Pınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, Kirstine Sandal Nørregaard, Henrik Gårdsvoll, Jingli Zhang, Henrik Jessen Jürgensen, Michaela Hansen Blomquist, Alba Martinez Perlado, Oliver Krigslund, Eric Santoni-Rugiu, Lars Henning Engelholm, Raffit Hassan, Niels Behrendt Abstract uPARAP is a collagen-internalizing receptor with emerging relevance as a therapeutic target.…
Read MoreMultiomic, Histologic, and scRNA-seq Profiling of Pleural Mesothelioma Reveals Negative Prognosis Associated With a Novel Uncommitted Molecular Phenotype
Journal of Thoracic Oncology 2025 November 28 [Link] David T Severson, Samuel Freyaldenhoven, Benjamin Wadowski, Yin P Hung, Travis Hughes, Beow Y Yeap, William G Richards, Sanna Laaksonen, Lucian Chirieac, Matthew B Couger, Roderick V Jensen, Ahmed A Sadek, Ilkka Ilonen, Kimberly Vermilya, Simona Innocenti, Stephanie L Korle, Julianne S Barlow, Jamie Anderson, Jason Meyerovitz,…
Read MoreUse of Patient-Derived Organoids for Pleural Mesothelioma 3D modelling
American Journal of Physiology Lung Cellular and Molecular Physiology 2025 October 29 [Link] Luca Volpini, Federica Monaco, Elisabetta Casalone, Elton Jalis Herman, Rebecca Filomena, Sandra Manzotti, Olga Strogovets, Gianluca Moroncini, Matteo Mozzicafreddo, Antonella Poloni, Elena Marinelli Busilacchi, Francesca Gonnelli, Francesca Barbisan, Gaia Goteri, Lina Zuccatosta, Martina Bonifazi, Giuseppe Matullo, Jiri Neuzil, Lory Santarelli, Najib M…
Read MoreMalignant Local Seeding in Procedure Tracts of Pleural Mesothelioma: Incidence and Novel Risk Factors in 308 Patients
Cancers 2025 August 26 [Link] Moshe Lapidot, Emanuele Mazzola, Raphael Bueno Abstract Background/Objectives: Unlike other thoracic malignancies, seeding malignant cells along surgical tracts is a known complication of invasive diagnostic or therapeutic procedures for pleural mesothelioma (PM). We report the tract dissemination rate and risk factors in 308 consecutive patients treated over 9 years in…
Read MorePerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Nature Medicine 2025 September 8 [Link] Joshua E Reuss, Paul K Lee, Reza J Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong Meng, Gavin Pereira, Samira Hosseini-Nami, Mark Sausen, Marianna Zahurak, Richard J Battafarano, Russell K Hales, Joseph Friedberg, Boris Sepesi, Julie S Deutsch, Tricia Cottrell, Janis…
Read MoreMolecular expression of glycosaminoglycans modifies the plasticity of biphasic mesothelioma in favor of tumor progression
Glycoconjugate Journal 2025 August 13 [Link] Camila Machado Baldavira, Aline Nery Qualiotto, Tabatha Gutierrez Prieto, Sandra de Morais Fernezlian, Aline Assato, Marcelo Balancin, Teresa Takagaki, Alexandre Ab’Saber, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Vera Luiza Capelozzi Abstract The study aimed to verify whether the expression of glycosaminoglycans (GAGs) and proteoglycans (PGs) in the tumor…
Read MoreSignificance of 18F-fluorodeoxyglucose PET/computed tomography in the initial staging of malignant peritoneal mesothelioma
Nuclear Medicine Communications 2025 May 6 [Link] Hui Zhang, Lifang Pang, Jun Hou, Beilei Li, Yiqiu Zhang Abstract Objective: This study was aimed at evaluating the significance of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) in the staging and differentiation of malignant peritoneal mesothelioma (MPeM). Materials and methods: We retrospectively analyzed clinical and imaging data of 21…
Read MoreFollow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA
ESMO Open 2025 February [Link] L H Douma, M M Hofman, F Zwierenga, T M T Zondervan, A I G Buma, H Schouwink, D W Dumoulin, J A Burgers, I Smesseim, J G J V Aerts, C J de Gooijer Abstract Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic…
Read MoreAnalysis of Pleiotropic Effects of Nivolumab in Patients with Relapsed Pleural Mesothelioma: A Single-Center Retrospective Study
Oncology 2025 January 24 [Link] Tomoki Higashiyama, Kozo Kuribayashi, Hiroshi Doi, Aki Kubota, Taiichiro Otsuki, Yasuhiro Nakajima, Koji Mikami, Ryo Takahashi, Akifumi Nakamura, Daichi Fujimoto, Kazuhiro Kitajima, Toshiyuki Minami, Takashi Kijima Abstract Introduction: In August 2018, the Japanese PMDA approved nivolumab, an immune checkpoint inhibitor, for previously treated, unresectable, advanced, or recurrent pleural mesothelioma (PM)…
Read MoreReal-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study
Asia-Pacific Journal of Clinical Oncology 2024 December [Link] Kar Ven Cavan Chow, Cassie Turner, Brett Hughes, Zarnie Lwin, Bryan Chan Abstract Aim: To evaluate the real-world treatment patterns and outcomes for patients with pleural mesothelioma (PM) in the era of immunotherapy. Methods: This retrospective audit included patients with PM diagnosed within three tertiary referral centers…
Read More
Skip to content